Barrett's Esophagus - 315 - 3 Way Cross-Over

Study identifier:315

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Double-blind, three-way crossover intraesophageal and Intragastric pH Study of Three Esomeprazole Treatment Regimens in Documented Barrett's Esophagus Patients

Medical condition

Barrett's esophagus

Phase

Phase 4

Healthy volunteers

No

Study drug

Esomeprazole Magnesium

Sex

All

Actual Enrollment

50

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Mar 2002
Primary Completion Date: 01 Apr 2003
Study Completion Date: 01 Apr 2003

Study design

Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria